Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study (ASA)
|ClinicalTrials.gov Identifier: NCT01628315|
Recruitment Status : Completed
First Posted : June 26, 2012
Last Update Posted : February 12, 2016
- To examine short- and long-term value of appearance of new active lesions in predicting extent of cortical and subcortical deep gray matter (SDGM) atrophy over 5 years in ASA (Avonex- Steroid-Azathioprine)study.
- To explore how accumulation of cortical and SDGM atrophy over 5 years differs with respect to the number of new active lesions or amount of disease activity, in early relapsing-remitting multiple sclerosis (RRMS) patients who did or did not develop sustained disability progression.
- To examine the relationship between development of cortical and SDGM atrophy and regional likelihood of development of new active lesions over 5 years.
|Condition or disease||Intervention/treatment|
|Multiple Sclerosis, Relapsing-remitting||Device: MRI|
Historically, MS has been classified as a disease predominantly affecting the white matter (WM) of the central nervous system. However, pathological changes in gray matter (GM) are increasingly recognized as an important component of the MS disease process. Advances in MRI have enabled detection of changes in GM morphology.
The ASA study was a placebo-controlled trial that evaluated efficacy of Avonex® alone and in combination with azathioprine (AZA) or AZA and corticosteroids as initial MS therapy in 181 patients with early RRMS over 5 years. The study was conducted in the Czech Republic, and all clinical and MRI examinations were concluded at 5 years.
No study has evaluated the evolution of cortical and SDGM atrophy in relation to global or regional accumulation of active lesions and/or occurrence of relapses both from predictive short- and long-term perspective. The ASA study provides a unique opportunity to prospectively study the impact of cortical and SDGM atrophy accumulation on long-term disability progression in a defined cohort of early RRMS patients who presented with various amount of disease activity, as measured by the appearance of new active lesions and occurrence of relapses.
By assessing lesion activity in the 0-6 and 6-12 months in the ASA study we will be able to evaluate predictive value for development of cortical and SDGM atrophy in early RRMS patients over 5 years with respect to the number of new active lesions or amount of disease activity in the first year. We will also evaluate lesion development from 12-60 months in relation to development of cortical and SDGM atrophy. We will also analyze accumulation of cortical and SDGM atrophy in early RRMS patients who will or will not develop sustained disability progression, based on the number of new active lesions or amount of clinical and MRI disease activity in short- and long-term. Regional classification of new active lesions over 5 years in cortical, subcortical and fossa posterior will allow prospective examination of cortical and SDGM atrophy and appearance of the new lesions.
|Study Type :||Observational|
|Actual Enrollment :||159 participants|
|Official Title:||Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study|
|Study Start Date :||March 2009|
|Actual Primary Completion Date :||March 2009|
|Actual Study Completion Date :||December 2014|
Patients with relapsing-remitting MS who had a MRI as part of their participation in the ASA study.
Annual MRIs as part of participation in the ASA study.
- Lesion Activity [ Time Frame: 5 years ]Assessment of lesion activity in the 0-6 and 6-12 months in the ASA study will allow the classification of patients with respect to the number of new active lesions over short-term (over 1 year) in order to examine predictive value of MRI disease activity in relation to development of long-term (5 year) cortical and SDGM atrophy.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01628315
|United States, New York|
|Buffalo Neuroimaging Analysis Center|
|Buffalo, New York, United States, 14203|
|Principal Investigator:||Robert Zivadinov, MD,PhD,FAAN||Buffalo Neuroimaging Analysis Center|